APOA5

APOA5

A gene on chromosome 11q23 that encodes apolipoprotein A-V, a minor apolipoprotein mainly associated with high-density lipoprotein (HDL), less so with VLDL and chylomicrons. It is an important determinant of plasma triglyceride (TG) levels, both stimulating TG hydrolysis by apo-CII lipoprotein lipase and inhibiting VLDL-TG production.
References in periodicals archive ?
4] Human genes: APOA5, apolipoprotein A-V; PDGFRB, platelet-derived growth factor receptor beta; LDLRAP1, low density lipoprotein receptor adaptor protein 1; MMP9, matrix metallopeptidase 9; VEGFA, vascular endothelial growth factor A; ACTA2, actin, alpha 2, smooth muscle, aorta; APOC3, apolipoprotein C-III; CAV1, caveolin 1; CD40, CD40 molecule; CETP, cholesterol ester transfer protein, plasma; CIITA, class II, major histocompatibility complex, transactivator; FGG, fibrinogen gamma chain; GPX1, glutathione peroxidase 1; LPL, lipoprotein lipase; MBL2, mannose-binding lectin (protein C)2,soluble; MVK, mevalonate kinase; PITX2, paired like homeodomain 2; TNFRSF1A, tumor necrosis factor receptor superfamily, member 1A; UCP2, uncoupling protein 2 (mitochondrial, protein carrier).
Additive effects of APOE, APOA5 and LPL, variants combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study.
The study, which was published in the Journal of Lipid Research, sought to appraise the relationship of carriers of variants of the APOA5 gene to atherosclerosis, or hardening of the arteries.
Collaborating with Roberto Elosua and Chao Qiang Lai, he appraised the relationship of carriers of variants of the APOA5 gene to atherosclerosis, or hardening of the arteries.
Finally, participants were genotyped for 3 polymorphisms in TRIB1 (tribbles pseudokinase 1) (rs2954029), GCKR [glucokinase (hexokinase 4) regulator] (rs1260326), and APOA5 (apolipoprotein A-V) (rs651821) that also reduce plasma nonfasting triglycerides (13), and these were included in sensitivity analyses.
The associations of CHD and stroke with the--1131T>C promoter polymorphism of the APOA5 (apolipoprotein A-V) gene, which is the chief genetic determinant of triglyceride concentrations, were assessed.
The role of APOA5 in regulating TG metabolism has been convincingly demonstrated in animal models (8) and in a large number of association studies (9), in which the -1131T [right arrow] C is the commonly used variant.
Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges.
Genetic variation in APOA5 has been consistently associated with plasma triglyceride concentrations in several studies (2-4).